Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OPK Stock Summary
Top 10 Correlated ETFs
OPK
In the News
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time.
3 Stocks with Major Insider Buying This Month
Active traders use many fundamental or technical signals to set up their trades. Stocks exhibiting heavy insider buying can be one of these signals.
More Big Warren Buffett Purchases Highlight Recent Insider Buying
The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.
OPK Financial details
OPK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.51 | 2.24 | 2.74 | 1.4 | 1.15 | |
Net income per share | -0.52 | 0.05 | -0.05 | -0.46 | -0.25 | |
Operating cash flow per share | -0.29 | 0.06 | 0.06 | -0.13 | -0.04 | |
Free cash flow per share | -0.31 | 0.01 | 0.01 | -0.17 | -0.06 | |
Cash per share | 0.14 | 0.11 | 0.21 | 0.21 | 0.13 | |
Book value per share | 2.71 | 2.61 | 2.6 | 2.17 | 1.85 | |
Tangible book value per share | -0.54 | -0.44 | 0.08 | 0.24 | -0.19 | |
Share holders equity per share | 2.71 | 2.61 | 2.6 | 2.17 | 1.85 | |
Interest debt per share | 0.43 | 0.44 | 0.36 | 0.31 | 0.37 | |
Market cap | 875.32M | 2.53B | 3.12B | 898.83M | 1.14B | |
Enterprise value | 1B | 2.68B | 3.17B | 959.13M | 1.37B | |
P/E ratio | -2.81 | 82.74 | -105.67 | -2.74 | -6.01 | |
Price to sales ratio | 0.97 | 1.76 | 1.76 | 0.9 | 1.31 | |
POCF ratio | -5.07 | 64.1 | 81.31 | -9.44 | -40.26 | |
PFCF ratio | -4.72 | 436.76 | 504.33 | -7.5 | -25.53 | |
P/B Ratio | 0.54 | 1.51 | 1.85 | 0.58 | 0.82 | |
PTB ratio | 0.54 | 1.51 | 1.85 | 0.58 | 0.82 | |
EV to sales | 1.11 | 1.87 | 1.79 | 0.96 | 1.58 | |
Enterprise value over EBITDA | -18.44 | 25.26 | 1.22K | -5.38 | -25.89 | |
EV to operating cash flow | -5.8 | 67.9 | 82.7 | -10.08 | -48.44 | |
EV to free cash flow | -5.4 | 462.61 | 512.94 | -8.01 | -30.71 | |
Earnings yield | -0.36 | 0.01 | -0.01 | -0.36 | -0.17 | |
Free cash flow yield | -0.21 | 0 | 0 | -0.13 | -0.04 | |
Debt to equity | 0.15 | 0.15 | 0.13 | 0.14 | 0.19 | |
Debt to assets | 0.1 | 0.1 | 0.09 | 0.1 | 0.13 | |
Net debt to EBITDA | -2.32 | 1.41 | 20.46 | -0.34 | -4.37 | |
Current ratio | 1.3 | 1.39 | 2.73 | 1.85 | 1.55 | |
Interest coverage | -9.14 | 2.63 | -2.53 | -20.42 | -11.7 | |
Income quality | 0.55 | 1.29 | -1.27 | 0.29 | 0.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.13 | 0.05 | 0.04 | 0.07 | 0.1 | |
Intangibles to total assets | 0.55 | 0.51 | 0.46 | 0.36 | 0.76 | |
Capex to operating cash flow | 0.07 | -0.85 | -0.84 | 0.26 | 0.58 | |
Capex to revenue | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | |
Capex to depreciation | -0.14 | -0.39 | -0.41 | -0.23 | -0.15 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
Graham number | 5.65 | 1.67 | 1.63 | 4.72 | 3.23 | |
ROIC | -0.11 | 0.02 | -0.05 | -0.11 | -0.09 | |
Return on tangible assets | -0.3 | 0.03 | -0.02 | -0.24 | -0.39 | |
Graham Net | -0.78 | -0.68 | -0.52 | -0.42 | -0.53 | |
Working capital | 74.9M | 147.7M | 521.2M | 181M | 109.42M | |
Tangible asset value | 352.7M | 400.8M | 574.3M | 770.7M | -144.32M | |
Net current asset value | -370.5M | -278.3M | 108.4M | -211.2M | -313M | |
Invested capital | 0.15 | 0.15 | 0.13 | 0.14 | 0.19 | |
Average receivables | 159.84M | 229.97M | 283.92M | 207.1M | 139.4M | |
Average payables | 54.97M | 81.71M | 91.46M | 74.52M | 68.34M | |
Average inventory | 47.87M | 92.89M | 109.42M | 80.28M | 69.88M | |
Days sales outstanding | 63.82 | 76.86 | 54.62 | 54.02 | 55.04 | |
Days payables outstanding | 39.87 | 41.17 | 25.1 | 34.16 | 40.28 | |
Days of inventory on hand | 34.07 | 54.01 | 26.46 | 37.75 | 37.98 | |
Receivables turnover | 5.72 | 4.75 | 6.68 | 6.76 | 6.63 | |
Payables turnover | 9.15 | 8.87 | 14.54 | 10.69 | 9.06 | |
Inventory turnover | 10.71 | 6.76 | 13.79 | 9.67 | 9.61 | |
ROE | -0.19 | 0.02 | -0.02 | -0.21 | -0.14 | |
Capex per share | -0.02 | -0.05 | -0.05 | -0.03 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.25 | 0.32 | 0.35 | 0.24 | 0.24 | |
Net income per share | -0.11 | -0.02 | -0.03 | -0.11 | -0.09 | |
Operating cash flow per share | -0.04 | -0.03 | 0 | 0.04 | -0.05 | |
Free cash flow per share | -0.05 | -0.03 | -0.01 | 0.04 | -0.05 | |
Cash per share | 0.2 | 0.15 | 0.14 | 0.18 | 0.13 | |
Book value per share | 2.08 | 2.06 | 2.04 | 1.92 | 1.85 | |
Tangible book value per share | 0.23 | 0.2 | -0.05 | 0.12 | -0.19 | |
Share holders equity per share | 2.08 | 2.06 | 2.04 | 1.92 | 1.85 | |
Interest debt per share | 0.29 | 0.32 | 0.4 | 0.33 | 0.36 | |
Market cap | 937.71M | 1.1B | 1.63B | 1.2B | 1.13B | |
Enterprise value | 998.01M | 1.2B | 1.82B | 1.28B | 1.37B | |
P/E ratio | -2.75 | -15.07 | -20.76 | -3.56 | -4.27 | |
Price to sales ratio | 5.06 | 4.62 | 6.15 | 6.73 | 6.24 | |
POCF ratio | -29.66 | -48.45 | -4.47K | 36.32 | -29.63 | |
PFCF ratio | -24.71 | -42.72 | -255.76 | 41.6 | -27.47 | |
P/B Ratio | 0.6 | 0.71 | 1.06 | 0.83 | 0.82 | |
PTB ratio | 0.6 | 0.71 | 1.06 | 0.83 | 0.82 | |
EV to sales | 5.38 | 5.04 | 6.85 | 7.15 | 7.51 | |
Enterprise value over EBITDA | -24.16 | -134.57 | 137.81 | -28.32 | -31.67 | |
EV to operating cash flow | -31.56 | -52.89 | -4.98K | 38.57 | -35.66 | |
EV to free cash flow | -26.29 | -46.63 | -285.17 | 44.18 | -33.05 | |
Earnings yield | -0.09 | -0.02 | -0.01 | -0.07 | -0.06 | |
Free cash flow yield | -0.04 | -0.02 | 0 | 0.02 | -0.04 | |
Debt to equity | 0.14 | 0.16 | 0.19 | 0.18 | 0.19 | |
Debt to assets | 0.1 | 0.11 | 0.14 | 0.12 | 0.13 | |
Net debt to EBITDA | -1.46 | -11.29 | 14.21 | -1.66 | -5.35 | |
Current ratio | 1.85 | 1.83 | 1.92 | 1.78 | 1.55 | |
Interest coverage | -17.9 | 8.99 | 2.14 | 19.03 | -20.01 | |
Income quality | 0.37 | 1.24 | 0.02 | -0.39 | 0.58 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.01 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.11 | 0.14 | 0.07 | 0.11 | 0.11 | |
Intangibles to total assets | 0.36 | 0.37 | 0.73 | 0.38 | 0.76 | |
Capex to operating cash flow | 0.2 | 0.13 | 16.47 | -0.13 | 0.08 | |
Capex to revenue | -0.03 | -0.01 | -0.02 | -0.02 | -0.02 | |
Capex to depreciation | -0.24 | -0.11 | -0.23 | -0.16 | -0.12 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
Graham number | 2.31 | 1.06 | 1.1 | 2.21 | 1.92 | |
ROIC | -0.03 | -0.02 | 0 | -0.04 | -0.04 | |
Return on tangible assets | -0.06 | -0.01 | -0.03 | -0.07 | -0.14 | |
Graham Net | -0.41 | -0.5 | -0.41 | -0.47 | -0.53 | |
Working capital | 181M | 184M | 207.34M | 156.6M | 109.42M | |
Tangible asset value | 770.7M | 759.4M | -39.22M | 655.1M | -144.32M | |
Net current asset value | -211.2M | -211.4M | -189.76M | -254.9M | -313M | |
Invested capital | 0.14 | 0.16 | 0.19 | 0.18 | 0.19 | |
Average receivables | 143.43M | 135.05M | 174.79M | 172.77M | 123.82M | |
Average payables | 58.37M | 73.75M | 84.19M | 77.34M | 68.24M | |
Average inventory | 72.74M | 74.74M | 74.58M | 71.35M | 67.33M | |
Days sales outstanding | 72.14 | 46.02 | 77.34 | 59.18 | 64.42 | |
Days payables outstanding | 46.6 | 52.39 | 56.92 | 45.93 | 39.51 | |
Days of inventory on hand | 51.51 | 49.07 | 47.77 | 47.41 | 37.26 | |
Receivables turnover | 1.25 | 1.96 | 1.16 | 1.52 | 1.4 | |
Payables turnover | 1.93 | 1.72 | 1.58 | 1.96 | 2.28 | |
Inventory turnover | 1.75 | 1.83 | 1.88 | 1.9 | 2.42 | |
ROE | -0.05 | -0.01 | -0.01 | -0.06 | -0.05 | |
Capex per share | -0.01 | 0 | -0.01 | -0.01 | 0 |
OPK Frequently Asked Questions
What is OPKO Health, Inc. stock symbol ?
OPKO Health, Inc. is a US stock , located in Miami of Fl and trading under the symbol OPK
Is OPKO Health, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $3.5. The lowest prediction is $3 and the highest is $4
What is OPK stock prediction ?
What is OPKO Health, Inc. stock quote today ?
OPKO Health, Inc. stock price is $1.1754 today.
Is OPKO Health, Inc. stock public?
Yes, OPKO Health, Inc. is a publicly traded company.